Insulin-like growth factor 1 is a peptide hormone and growth mediator associated with growth hormone action. The liver supplies an important circulating source, and IGF-1 signalling helps coordinate growth of tissues including cartilage and bone. The regulatory pathway therefore connects a pituitary signal with growth-related responses in other tissues.[ref]
The motivating experiment was to look for a measurable activity in blood serum. A 1957 report by W. D. Salmon Jr. and William Daughaday examined a hormonally controlled serum factor through sulfate incorporation by cartilage in vitro.[ref] In his later account, William Daughaday described cartilage culture and sulfate uptake as the readout that motivated the hypothesis of a serum mediator of growth hormone action.[ref]
This was a functional assay: it detected what a serum preparation did to a tissue. Identifying the responsible molecules required further biochemical work. In 1978, E. Rinderknecht and R. E. Humbel reported structural homology between serum-derived IGF-I and proinsulin, providing a molecular basis for the insulin-like designation.[ref]
The historical progression connects three kinds of evidence: pituitary control, a tissue response to blood serum, and molecular identification of a protein. A serum bioactivity measurement and a measurement of one purified hormone answer different experimental questions.

Articles by others on the same topic (0)

There are currently no matching articles.